Shares Magazine
11.29p+0.39 (+3.56%)16 Dec 2025, 09:39
Jump to:
Allergy Therapeutics PLC Fundamentals
| Company Name | Allergy Therapeutics PLC | Last Updated | 2025-12-16 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 6.141 bn | Market Cap | £693.25 m |
| PE Ratio | 49.50 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.8896 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -2.3957 | Cash Equity Ratio | -0.4466 |
| Quick Ratio | 0.6610 | Current Ratio | 1.28 |
| Price To Book Value | 0 | ROCE | 0 |
Allergy Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Allergy Therapeutics PLC Company Financials
| Assets | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tangible Assets | £24.26 m | £23.75 m | £23.24 m | £20.19 m |
| Intangible Assets | £4.26 m | £4.69 m | £5.14 m | £5.04 m |
| Investments | 0 | 0 | 0 | 0 |
| Total Fixed Assets | £32.87 m | £32.92 m | £34.90 m | £30.55 m |
| Stocks | £13.91 m | £12.74 m | £11.59 m | £11.41 m |
| Debtors | £5.38 m | £5.40 m | £5.83 m | £9.21 m |
| Cash & Equivalents | £12.59 m | £12.71 m | £14.64 m | £20.32 m |
| Other Assets | 0 | 0 | 0 | 0 |
| Total Assets | £67.54 m | £66.41 m | £68.43 m | £72.95 m |
| Liabilities | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Creditors within 1 year | £27.19 m | £18.80 m | £18.57 m | £18.05 m |
| Creditors after 1 year | £68.54 m | £40.25 m | £45.75 m | £17.13 m |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | £95.74 m | £59.05 m | £64.32 m | £35.18 m |
| Net assets | -£28.19 m | £7.36 m | £4.11 m | £37.77 m |
| Equity | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Called up share capital | £4.77 m | £4.78 m | £689,000.00 | £644,000.00 |
| Share Premium | £154.65 m | £154.64 m | £119.03 m | £112.58 m |
| Profit / Loss | -£39.20 m | -£39.17 m | -£41.77 m | -£12.66 m |
| Other Equity | -£28.19 m | £7.36 m | £4.11 m | £37.77 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | -£28.19 m | £7.36 m | £4.11 m | £37.77 m |
| Ratios | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Debt Ratio | 0 | £0.80 | £0.89 | £0.18 |
| Debt-to-Equity | 0 | £3.92 | £8.32 | £0.22 |
| Assets / Equity | -2.3957 | -2.3957 | -2.3957 | -2.3957 |
| Cash / Equity | -0.4466 | -0.4466 | -0.4466 | -0.4466 |
| EPS | -£0.01 | -£0.01 | -£0.06 | -£0.02 |
| Cash Flow | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash from operating activities | -£28.11 m | -£32.14 m | -£28.88 m | -£14.00 m |
| Cashflow before financing | £3.05 m | -£707,000.00 | -£1.08 m | -£16.81 m |
| Increase in Cash | £168,000.00 | -£1.91 m | -£5.67 m | -£19.80 m |
| Income | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Turnover | £55.04 m | £55.20 m | £59.59 m | £72.77 m |
| Cost of sales | £25.74 m | £25.46 m | £26.34 m | £23.26 m |
| Gross Profit | £29.30 m | £29.74 m | £33.24 m | £49.51 m |
| Operating Profit | -£28.16 m | -£35.26 m | -£39.65 m | -£12.24 m |
| Pre-Tax profit | -£39.20 m | -£39.17 m | -£41.77 m | -£12.66 m |
Allergy Therapeutics PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK). |
| Latest Interim Date | 31 Mar 2025 |
| Latest Fiscal Year End Date | 11 Dec 2025 |
Allergy Therapeutics PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2025-12-11 | Dr. Babatunde Adekunle Otulana | Non-Executive Director,Senior Independent Director |
| 2025-12-11 | Mr. Peter Sinclair Jensen | Non-Executive Director,Chairman |
| 2014-10-08 | Mr. Alejandro Esteban Manieu Weinstein Jr | Non-Executive Director |
| 2011-10-21 | Dr. Thomas Alexander Hungerford Holdich | Executive Director,RandD Director |
| 2011-10-21 | Dr. Christian Gratz | Executive Director,Market Operations Director |
| 2016-09-26 | Mr. Ian David Postlethwaite | Executive Director,Finance Director and Company Secretary |
| 2012-06-29 | Ms. Ignace Robert Agnes Goethals | Non-Executive Director |
| 2021-11-22 | Mr. Stephen Rushworth Smith | Non-Executive Director,Senior Independent Director |
| 2025-12-11 | Mr. Manuel Llobet | Executive Director,Chief Executive Officer |
| 2012-06-29 | Dr. Virinder Nohria | Non-Executive Director |
| 2011-10-21 | Mr. Keith Iain Carter | Non-Executive Director |
| 2022-05-26 | Mr. Nicolas Alexander Ulrich Wykeman | Executive Director,Chief Financial Officer |
| 2025-12-11 | Mr. Zheqing Simon Shen | Non-Executive Director |
| 2025-12-11 | Mr. Anthony Michael Parker | Non-Executive Director |
| 2025-12-11 | Dr. Shaun Furlong | Executive Director,Chief Financial Officer |
Allergy Therapeutics PLC Contact Details
| Company Name | Allergy Therapeutics PLC |
|---|---|
| Address | Dominion Way, Worthing, BN14 8SA |
| Telephone | +44 1903844700 |
| Website | https://www.allergytherapeutics.com |
Allergy Therapeutics PLC Advisors
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Solicitor | Cooley LLP |
|---|---|
| Phone | +44 2075834055 |
| Fax | +44 2077859355 |
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Solicitor | Covington & Burling LLP |
|---|---|
| Phone | +44 2070672000 |
| Fax | +44 2070672222 |
| Auditor | Grant Thornton UK LLP |
|---|---|
| Phone | +44 1293554130 |
| Fax | +44 1293554135 |
| Bank | Royal Bank of Scotland PLC |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Ig Group Holdings PLC | 1,230.00 | 5.49 |
| Wizz Air Holdings PLC | 1,283.56 | 4.44 |
| B&M European Value Retail S.A. | 168.74 | 3.08 |
| Croda International PLC | 2,795.00 | 2.27 |
| Jd Sports Fashion PLC | 82.68 | 2.02 |
| Convatec Group PLC | 234.60 | 2.00 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Goodwin PLC | 19,800.00 | -8.33 |
| Ceres Power Holdings PLC | 251.00 | -5.71 |
| Babcock International Group PLC | 1,224.00 | -2.78 |
| Bae Systems PLC | 1,654.50 | -2.30 |
| Polar Capital Technology Trust PLC | 451.00 | -2.28 |
| Chemring Group PLC | 471.50 | -2.18 |